ライフサイエンスコーパス: regurgitant

1 two injured leaves treated with caterpillar regurgitant.

2 ponse to simulated attacks and produced less regurgitant.

3 he potential of providing direct measures of regurgitant and shunt flow.

4 lvular heart disease is the primary cause of regurgitant and stenotic valvular lesion in the U.S.

5 the natural history of combined stenotic and regurgitant aortic valve disease.

6 Repair of regurgitant aortic valves is not widely accepted, but in

7 te a new approach to bicommissural repair of regurgitant aortic valves.

8 volatile organic compounds after caterpillar regurgitant application.

9 This variant of the purely regurgitant BAV may cause either chronic AR (when the an

10 On the basis of the finding that caterpillar regurgitant can reduce the amount of toxic nicotine rele

11 sing stable isotope analysis of feathers and regurgitants collected from sooty terns (Onychoprion fus

12 The regurgitant contains a series of these compounds with fa

13 The presence of IAN in larval regurgitant contributes to reduced oviposition by adult

14 s replaced the mitral valve in patients with regurgitant disease.

15 rs (EMFs) as reference standards, and aortic regurgitant effective orifice areas (EOAs) were determin

16 the volume of regurgitation, the pattern of regurgitant flow across the mitral valve was not signifi

17 clinically observed midsystolic decrease in regurgitant flow and orifice area as transmitral pressur

18 have identified distinct patterns of mitral regurgitant flow disturbances in patients with mitral pr

19 UBM showed increasing abnormal regurgitant flow in the aorta and extending into the emb

20 emphysema at CT was associated with greater regurgitant flow in the superior and inferior caval vein

21 s study was to quantify and characterize the regurgitant flow pattern and regurgitant orifice area in

22 e the effect of dynamic variations of mitral regurgitant flow rate (MRFR) and effective regurgitant o

23 In functional mitral regurgitation (MR), regurgitant flow rate and orifice area display a unique

24 The continuity principle dictates that regurgitant flow rate can be calculated as the product o

25 size, and transmitral pressure, with direct regurgitant flow rate measurement, to test the hypothesi

26 r = 0.95, SEE = 0.05 cm, p < 0.0001 for peak regurgitant flow rate; r = 0.85, SEE = 0.08 cm, p < 0.00

27 =0.01 cm2) and between 3D and reference peak regurgitant flow rates and regurgitant stroke volumes (r

28 Peak regurgitant flow rates and regurgitant stroke volumes we

29 rifice areas (EOAs) were determined from EMF regurgitant flow rates divided by continuous-wave (CW) D

30 Instantaneous regurgitant flow rates were obtained by aortic and pulmo

31 Instantaneous regurgitant flow rates were obtained by aortic and pulmo

32 MR was quantified as peak and mean regurgitant flow rates, regurgitant stroke volumes and r

33 er workstation, the RV forward and pulmonary regurgitant flow volumes were obtained by a program that

34 integral (VTI) = midsystolic MRFR by PISA x regurgitant flow VTI/peak velocity; 2) simplified PISA =

35 R caused similar color jet area, midsystolic regurgitant flow, and peak velocity (P>0.40).

36 a provides an accurate direct measurement of regurgitant flow, overcoming the limitations of existing

37 vena contracta (VC-W), the smallest area of regurgitant flow, reflects the degree of valvular regurg

38 flow tract forward flow and ascending aortic regurgitant flow.

39 data for color Doppler imaging of the aortic regurgitant flows were transferred into a TomTec compute

40 We also observed differences between regurgitant (foregut) and midgut bacterial communities o

41 h high accuracy: 85% of the 39 subjects with regurgitant fraction >33% progressed to surgery (mostly

42 s) in comparison with 8% of 74 subjects with regurgitant fraction </= 33% (P<0.0001); the area under

43 A similar separation was observed for regurgitant fraction </=40% and >40%.

44 t pulmonary regurgitation (less than mild or regurgitant fraction <10% on magnetic resonance imaging

45 Peak E wave velocity correlated with regurgitant fraction (r = 0.52, p < 0.001).

46 The MR Index correlated with regurgitant fraction (r = 0.76, p < 0.0001).

47 icantly correlated with reductions in mitral regurgitant fraction (r = 0.77, p < 0.001).

48 rea (EROA), regurgitant volume (RegVol), and regurgitant fraction (RegFrac).

49 e quantitation of regurgitant volume (RVol), regurgitant fraction (RF) and effective regurgitant orif

50 AR was quantified using regurgitant fraction (RF) measured by phase-contrast vel

51 ejection fraction, RV volumes, and pulmonary regurgitant fraction (RF).

52 us intraoperative flow probe measurements of regurgitant fraction (RgF) and regurgitant volume (RgV).

53 re at 90 days corrected the volume overload (regurgitant fraction 6 +/- 5% versus 27 +/- 16% for late

54 nd C statistics) was performed, with HDR and regurgitant fraction as independent predictors.

55 er, ICC >= 0.99) and strong to excellent for regurgitant fraction assessment (intraobserver, ICC >= 0

56 volume from 40 +/- 20 ml to 24 +/- 17 ml and regurgitant fraction from 40 +/- 12% to 25 +/- 14% (both

57 to quantitate aortic regurgitant volume and regurgitant fraction in a chronic animal model with surg

58 Pulmonary regurgitant fraction increased from 32.8+/-15% to 49.6+/

59 Over time, aortic regurgitant fraction increased slightly but significantl

60 In animals with PI, pulmonary regurgitant fraction progressed more in the presence of

61 8), but the combination of this measure with regurgitant fraction provided the best discriminatory po

62 c magnetic resonance imaging RVol r=0.84 and regurgitant fraction r=0.80.

63 evaluation by an expert and quantitation of regurgitant fraction using two-dimensional and Doppler e

64 evaluation by an expert and quantitation of regurgitant fraction using two-dimensional and Doppler e

65 Regurgitant fraction varied between grafts, with SG and

66 lar ejection fraction was 60+/-8%, pulmonary regurgitant fraction was 34+/-17%, and right ventricular

67 ed across the pulmonary valve, the pulmonary regurgitant fraction was 37%; this was not seen in the a

68 In the PI group, pulmonary regurgitant fraction was 49.2+/-5.9% at 3-month follow-u

69 Regurgitant fraction was consistently >50% over the cour

70 A strong decline in pulmonary regurgitant fraction was observed after hTPV implantatio

71 Although overall differences in NFV and regurgitant fraction were comparable between both method

72 Pulmonary flow volumes and regurgitant fraction were quantified by velocity-encoded

73 1.2 +/- 7.6% vs. 19 +/- 13%, p < 0.0001 for regurgitant fraction).

74 ume; r = 0.90, SEE = 0.07 cm, p < 0.0001 for regurgitant fraction).

75 ted leaflet closure and mild-to-moderate MR (regurgitant fraction, 25.2+/-2.8%).

76 tricle-to-left atrial shunt implanted in 12 (regurgitant fraction, 30%).

77 mL, 50%, and 40 mm2 for regurgitant volume, regurgitant fraction, and orifice, respectively.

78 is feasible, significantly reduces pulmonary regurgitant fraction, facilitates right ventricular volu

79 ble right ventricular function and pulmonary regurgitant fraction, on exercise stress test the 22q11.

80 added little to the discriminatory power of regurgitant fraction/volume alone.

81 The RSVs and regurgitant fractions (RFs) obtained by the DCD method u

82 th SG and Uni-Graft groups having the lowest regurgitant fractions and anticommissural plication havi

83 Regurgitant volumes and regurgitant fractions by the new method agreed well with

84 As a result of these measurements, the regurgitant fractions derived by the 3D method agreed we

85 t flow rates, regurgitant stroke volumes and regurgitant fractions determined using mitral and aortic

86 rial shunt implanted, consistently producing regurgitant fractions of approximately 30%.

87 lysis times, net forward volumes (NFVs), and regurgitant fractions.

88 etermining pulmonary regurgitant volumes and regurgitant fractions.

89 oderate mitral regurgitation) and changes in regurgitant grade at each heart valve were evaluated.

90 rgitant orifice causes, despite a decline in regurgitant gradient, a notable increase in regurgitant

91 ied 27 patients with severe TR, defined by a regurgitant index (RI) >33%, who underwent PTE.

92 ntinuous wave Doppler characteristics of the regurgitant jet and tricuspid regurgitant jet-derived pu

93 x echocardiographic variables: color Doppler regurgitant jet penetration and proximal isovelocity sur

94 Patients with a tricuspid-valve regurgitant jet velocity >/=3.2 m/s (3.6%) on transthora

95 ive predictive value for the tricuspid-valve regurgitant jet velocity >/=3.2 m/s threshold for the di

96 An elevated tricuspid regurgitant jet velocity (TRV) is associated with hemoly

97 y associated with PH, defined as a tricuspid regurgitant jet velocity (TRV) of at least 2.5 m/s.

98 Abnormal tricuspid regurgitant jet velocity (TRV) was defined as more than

99 d vascular complications (elevated tricuspid regurgitant jet velocity [TRV], microalbuminuria, leg ul

100 g echocardiography to measure peak tricuspid regurgitant jet velocity and by evaluating plasma levels

101 nsion and correlated directly with tricuspid regurgitant jet velocity in the NIH cohort (R = 0.50, P<

102 A tricuspid regurgitant jet velocity of at least 2.5 m per second, a

103 ion was prospectively defined as a tricuspid regurgitant jet velocity of at least 2.5 m per second.

104 e of the dichotomous variable of a tricuspid regurgitant jet velocity of less than 2.5 m per second o

105 Elevated tricuspid regurgitant jet velocity, pulmonary hypertension, diasto

106 Methods to directly measure the regurgitant jet vena contracta area are presented, along

107 The mitral regurgitant jet was central in origin in 12 group 1 pati

108 nar flow acceleration zone and the turbulent regurgitant jet, has been reported to be a clinically us

109 ristics of the regurgitant jet and tricuspid regurgitant jet-derived pulmonary artery pressure, pulse

110 of the mitral leaflets at the origin of the regurgitant jet.

111 lic volume index, and the area of the mitral regurgitant jet; increased the left ventricular ejection

112 precise anatomy, and visualization of mitral regurgitant jets in mitral valve prolapse.

113 There were multiple regurgitant jets in three of five (60%) patients in this

114 hat this held only for laminar flow, not for regurgitant jets, in which turbulence and fluid entrainm

115 also to help discern the consequences of the regurgitant lesion on left ventricular performance.

116 accuracy and outcome implications of mitral regurgitant lesions assessed by echocardiography.

117 Recent efforts into the inflow position and regurgitant lesions, with transcatheter repair and repla

118 s synergism suggests that contents in animal regurgitants making their way into plant tissue during f

119 accepted method for the surgical repair of a regurgitant mitral valve.

120 Currently, over 90% of regurgitant mitral valves of varying etiologies are amen

121 us, exercise duration, LVOT gradient, mitral regurgitant (MR) volume, LV pre-A pressure and LA volume

122 We identified bacteria from the regurgitant of field-collected Helicoverpa zea larvae us

123 (17-hydroxylinolenoyl-l-Gln) present in the regurgitant of Spodoptera exigua (beet armyworm caterpil

124 lass of compounds has been isolated from the regurgitant of the grasshopper species Schistocerca amer

125 r, there were only low detectable amounts of regurgitant or bacteria on H. zea-damaged tomato leaves.

126 tion was demonstrated by increased effective regurgitant orifice (0.21 cm(2); 25th to 75th percentile

127 rgitant volume increased less than effective regurgitant orifice (120 [25th to 75th percentile, 78.6

128 esence of diabetes, and increasing effective regurgitant orifice (adjusted risk ratio per 10-mm2 incr

129 01) were obtained between VC-W and effective regurgitant orifice (ERO) area and regurgitant volume re

130 nts, regurgitant volume (RVol) and effective regurgitant orifice (ERO) area were 36+/-24 mL/beat and

131 The VCW correlated well with the effective regurgitant orifice (ERO) by the flow convergence method

132 Whether effective regurgitant orifice (ERO) by the flow convergence method

133 a (PISA) method for calculation of effective regurgitant orifice (ERO) of aortic regurgitation (AR).

134 ltaneously by echocardiography the effective regurgitant orifice (ERO) of FMR by using 2 methods: mit

135 ol), regurgitant fraction (RF) and effective regurgitant orifice (ERO) to define progression of MR.

136 sions (all P>0.55), and mitral regurgitation regurgitant orifice (P=0.62).

137 ms, 48.8 [14.8 to 161]) and mitral effective regurgitant orifice (r = 0.50, p = 0.0001; odds ratio [9

138 hic quantitation of IMR (measuring effective regurgitant orifice [ERO] and regurgitant volume).

139 ocardiographic quantitation of MR (effective regurgitant orifice [ERO]) and left ventricular (LV) sys

140 does not require spatial localization of the regurgitant orifice and can be performed semiautomatedly

141 ethod that eliminated the need to locate the regurgitant orifice and that could be performed semiauto

142 Direct measurements of the effective regurgitant orifice are also feasible and serve as an al

143 predicted a regurgitant volume < 60 mL and a regurgitant orifice area < 0.4 cm2 in 24 of 29 patients.

144 1 ml to 3.1 +/- 0.5 ml, p < 0.05), effective regurgitant orifice area (0.130 +/- 0.010 cm(2) to 0.040

145 The mean anatomic regurgitant orifice area (0.35+/-0.10 cm(2)) was underes

146 ume (69 +/- 47 to 69 +/- 56 ml) or effective regurgitant orifice area (0.5 +/- 0.4 to 0.5 +/- 0.6 cm2

147 Significant reductions in effective regurgitant orifice area (0.9+/-0.3cm(2) versus 0.4+/-0.

148 eduction in annular area (57%) and effective regurgitant orifice area (53%) measured with 3-dimension

149 =moderate chronic AR quantified by effective regurgitant orifice area (EROA) and regurgitant volume (

150 ion of severe secondary MR from an effective regurgitant orifice area (EROA) of 0.4 to 0.2 cm(2), and

151 l regurgitant flow rate (MRFR) and effective regurgitant orifice area (EROA) on mitral regurgitant st

152 edical therapy and assessed sMR by effective regurgitant orifice area (EROA), regurgitant volume (Reg

153 egurgitant volume (r = .85, SEE = 20 mL) and regurgitant orifice area (r = .86, SEE = 0.15 cm2).

154 Regurgitant orifice area (ROA) is an important measure o

155 graphic measurements (TA diameter, effective regurgitant orifice area [EROA], left ventricular stroke

156 Using an in vitro model of MR, the effective regurgitant orifice area and regurgitant volume (RVol) w

157 VCW, effective regurgitant orifice area and regurgitant volume were mea

158 ide was concordant with changes in effective regurgitant orifice area and regurgitant volume, and was

159 s of vena contracta and PISA-based effective regurgitant orifice area and regurgitant volume.

160 of heart failure through a reduction in the regurgitant orifice area but not through a change in the

161 patients (n=30, functional MR), 3D effective regurgitant orifice area correlated well with cardiac ma

162 In all patients, the regurgitant orifice area decreased with therapy from 0.5

163 determined as well as regurgitant volume and regurgitant orifice area derived from color M-mode and D

164 ly, increased transmitral pressure decreased regurgitant orifice area for any geometric configuration

165 ught to validate direct planimetry of mitral regurgitant orifice area from three-dimensional echocard

166 ted significantly with regurgitant volume or regurgitant orifice area in a multivariate analysis.

167 haracterize the regurgitant flow pattern and regurgitant orifice area in patients undergoing therapy

168 mmary, the time course and rate of change of regurgitant orifice area in patients with functional MR

169 Reduction of the regurgitant orifice area is likely related to decreased

170 Similarly, the rate of change of regurgitant orifice area more strongly related to that o

171 proximal isovelocity surface area effective regurgitant orifice area of 50% (0.8 cm(2) vs. 0.4 cm(2)

172 en LV end-diastolic volume and the effective regurgitant orifice area of the mitral valve.

173 All patients had midsystolic decreases in regurgitant orifice area that mirrored increases in tran

174 A similar regurgitant orifice area time course was observed in fou

175 ic volume was 192.7 +/- 71 ml, and effective regurgitant orifice area was 0.41 +/- 0.15 cm(2).

176 ve annular area of 14.1 cm(2), and effective regurgitant orifice area was 1.35 cm(2).

177 Effective regurgitant orifice area was calculated by dividing the

178 In 30 patients with functional MR, regurgitant orifice area was obtained as flow (from M-mo

179 vere primary degenerative MR (mean effective regurgitant orifice area, 0.45 +/- 0.25 cm)(2) with no c

180 te to severe mitral regurgitation (effective regurgitant orifice area, 38+/-18 mm(2)) and preserved l

181 sed regurgitant volume, PISA-based effective regurgitant orifice area, and vena contracta with agreem

182 d regurgitant volume, PISA-derived effective regurgitant orifice area, vena contracta, color Doppler

183 d transmitral pressure on dynamic changes in regurgitant orifice area.

184 ricuspid regurgitation (TR) by occupying the regurgitant orifice area.

185 transmitral pressure significantly affected regurgitant orifice area; however, transmitral pressure

186 g inspiration, a large increase in effective regurgitant orifice causes, despite a decline in regurgi

187 Effective regurgitant orifice changes are independently linked to

188 Effective regurgitant orifice during inspiration was independently

189 end-systolic dimension, and mitral effective regurgitant orifice increased the C-statistic for longer

190 tion does not predict accurately whether the regurgitant orifice is fixed or dynamic.

191 Patients with an effective regurgitant orifice of at least 40 mm2 had a five-year s

192 Patients with an effective regurgitant orifice of at least 40 mm2 should promptly b

193 As compared with patients with a regurgitant orifice of less than 20 mm2, those with an o

194 Mitral effective regurgitant orifice size (n=84) influenced RV EF (beta=-

195 ional mitral regurgitation (larger effective regurgitant orifice).

196 itant volume, 66+/-40 ml per beat; effective regurgitant orifice, 40+/-27 mm2).

197 tricular ejection fraction, mitral effective regurgitant orifice, indexed LV end-diastolic volume, an

198 Mean LVEF, mitral effective regurgitant orifice, indexed LV end-systolic diameter (L

199 tricular ejection fraction, mitral effective regurgitant orifice, resting right ventricular systolic

200 endocarditis were considered to have a fixed regurgitant orifice, whereas patients with mitral valve

201 ange in the force balance acting to create a regurgitant orifice, with rising transmitral pressure co

202 r ischemia were considered to have a dynamic regurgitant orifice.

203 gurgitation caused by dynamic changes in the regurgitant orifice.

204 not be load independent because of a dynamic regurgitant orifice.

205 nd Id-FTR were also matched for TR effective-regurgitant-orifice (ERO).

206 r alias contour with velocity va) divided by regurgitant peak velocity (obtained by continuous wave [

207 Vena contracta width correlated well with regurgitant severity determined by electromagnetic flowm

208 The pre-surgical estimate of regurgitant severity was correlated with the postoperati

209 AV-Vel, which reflects both stenosis and regurgitant severity, provides an objective and easily a

210 ve regurgitant orifice area (EROA) on mitral regurgitant stroke volume (MRSV) quantification using 4

211 ate; r = 0.85, SEE = 0.08 cm, p < 0.0001 for regurgitant stroke volume; r = 0.90, SEE = 0.07 cm, p <

212 nd reference peak regurgitant flow rates and regurgitant stroke volumes (r=0.99, difference=0.11 L/mi

213 Thirteen different forward and regurgitant stroke volumes (RSVs) across the noncircular

214 ied as peak and mean regurgitant flow rates, regurgitant stroke volumes and regurgitant fractions det

215 Peak regurgitant flow rates and regurgitant stroke volumes were calculated as the produc

216 right ventricular (RV) forward and pulmonary regurgitant stroke volumes.

217 column for direct visual recording of mitral regurgitant SV (MRSV).

218 nically damaged and induced with caterpillar regurgitant than seedlings not exposed to GLV.

219 Tricuspid regurgitant (TR) jet velocity and its relationship to pu

220 Quantitation of tricuspid regurgitant (TR) severity can be challenging with conven

221 d can be used in conjunction with quantified regurgitant values obtained from velocity-encoded MR ima

222 h of diagnosis, surgery was performed for 13 regurgitant valves in 11 patients (24%).

223 ves seen in 34 4D phase-contrast studies, 29 regurgitant valves were identified, with good agreement

224 linically to assess severity of stenotic and regurgitant valves.

225 Surgical treatment of stenotic or regurgitant valvular lesions can alter the natural histo

226 w, or pulmonary hypertension (peak tricuspid regurgitant velocity >2.5 m/s) should alert clinicians o

227 Elevated tricuspid regurgitant velocity (> or = 2.5 m/sec), a measure of pu

228 ic pressure (PASP) >35 mmHg and/or tricuspid regurgitant velocity (TRV) >2.5 m/s.

229 e cell disease (SCD), an increased tricuspid regurgitant velocity (TRV) measured by Doppler echocardi

230 to test whether the ratio of peak tricuspid regurgitant velocity (TRV, ms) to the right ventricular

231 Tricuspid regurgitant velocity and creatinine levels also did not

232 Baseline tricuspid regurgitant velocity, a measure of pulmonary systolic pr

233 nificant tricuspid regurgitation with a high regurgitant velocity.

234 ted with anemia, endothelin-1, and tricuspid regurgitant velocity; the latter is reflective of peak p

235 gnificantly more reduced in patients in whom regurgitant vena contracta area was reduced by >50% comp

236 without surgery compared with only 21% with regurgitant volume >55 mL (P<0.0001).

237 na contracta width < or = 0.3 cm predicted a regurgitant volume < 60 mL and a regurgitant orifice are

238 ndications for surgery: 91% of subjects with regurgitant volume </=55 mL survived to 5 years without

239 versus -37+/-21%), and percent mitral valve regurgitant volume (-99+/-2% versus -52+/-56%) for the X

240 /LA area 43 +/- 4% to 8 +/- 5%, p < 0.0001), regurgitant volume (14.7 +/- 2.1 ml to 3.1 +/- 0.5 ml, p

241 versus 426+/-50 ms; P<0.0001) yielded lower regurgitant volume (24.8+/-13.4 versus 48.6+/-25.6 mL; P

242 +/-0.5 cm versus 0.6+/-0.3 cm; P=0.001), and regurgitant volume (57.2+/-12.8 mL/beat versus 30.8+/-6.

243 ues for VCW (0.5 +/- 0.2 to 0.5 +/- 0.2 cm), regurgitant volume (69 +/- 47 to 69 +/- 56 ml) or effect

244 In the patients, mitral regurgitant volume (MRV) by ACMm-ACMa agreed with PD-2D

245 color Doppler methods for determining mitral regurgitant volume (MRV) have prevented their widespread

246 asternal long-axis view correlated well with regurgitant volume (r = .85, SEE = 20 mL) and regurgitan

247 hepatic venous flow (r = 0.79, p < 0.0001), regurgitant volume (r = 0.77, p<0.0001) and right atrial

248 y effective regurgitant orifice area (EROA), regurgitant volume (RegVol), and regurgitant fraction (R

249 asurements of regurgitant fraction (RgF) and regurgitant volume (RgV).

250 All patients underwent MRI to quantify regurgitant volume (RV) of OMR by subtracting the aortic

251 The regurgitant volume (Rvol) across the MV was obtained usi

252 In IMR patients, regurgitant volume (RVol) and effective regurgitant orif

253 ffective regurgitant orifice area (EROA) and regurgitant volume (RVol) from 2004 to 2017 who had >=1

254 We hypothesized that CMR measurement of regurgitant volume (RVol) is more reproducible than TTE.

255 area (EROA) of 0.4 to 0.2 cm(2), and from a regurgitant volume (RVol) of 60 to 30 ml.

256 , the effective regurgitant orifice area and regurgitant volume (RVol) were measured by the PISA tech

257 diographic methods allow the quantitation of regurgitant volume (RVol), regurgitant fraction (RF) and

258 itutions and presenting moderate SMR (mitral regurgitant volume 30 to 45 mL/beat) not considered for

259 had a mean ejection fraction 64 +/- 9%, mean regurgitant volume 67 +/- 31 ml, and low mean Charlson c

260 s, 60% men) in sinus rhythm with organic MR (regurgitant volume 68 +/- 42 ml/beat) and performed at b

261 al TEE demonstrates significant reduction of regurgitant volume after PMVR.

262 Mitral regurgitant volume and orifice area did not correlate wi

263 f the present study was to quantitate aortic regurgitant volume and regurgitant fraction in a chronic

264 raphic dimensions were determined as well as regurgitant volume and regurgitant orifice area derived

265 valve closure, increased the early systolic regurgitant volume before complete coaptation, and decre

266 Mitral valve regurgitant volume by color Doppler 3D TEE was determine

267 because the heart compensates for increasing regurgitant volume by left-atrial enlargement, causes le

268 orifice area was calculated by dividing the regurgitant volume by the continuous-wave Doppler veloci

269 Mitral regurgitant volume calculated from R(calc) and R(meas) c

270 The mitral regurgitant volume decreased from 47+/-27 ml before ther

271 ric method consistently decreased after CRT: regurgitant volume from 40 +/- 20 ml to 24 +/- 17 ml and

272 ) to be independently associated with mitral regurgitant volume improvement.

273 The added regurgitant volume in MR increases the left atrial to le

274 As a result of reduced TR driving force, regurgitant volume increased less than effective regurgi

275 sociated with postoperative change in mitral regurgitant volume on univariable analysis were entered

276 tive MR grade, correlated significantly with regurgitant volume or regurgitant orifice area in a mult

277 ted in context, and in mid-late systolic MR, regurgitant volume provides information more reflective

278 effective regurgitant orifice (ERO) area and regurgitant volume recorded by quantitative Doppler (r=0

279 Regurgitant volume was reduced from 84.1+/-38.3 mL prein

280 Mitral regurgitant volume was then calculated according to the

281 VCW, effective regurgitant orifice area and regurgitant volume were measured by quantitative Doppler

282 ht ventricular stroke volume minus pulmonary regurgitant volume) after BMS remained unchanged (33.8+/

283 ring effective regurgitant orifice [ERO] and regurgitant volume).

284 tified according to current recommendations (regurgitant volume, 66+/-40 ml per beat; effective regur

285 es in effective regurgitant orifice area and regurgitant volume, and was not different between dynami

286 However, shorter MR yields lower regurgitant volume, consequences, and benign outcomes.

287 concordance when only considering PISA-based regurgitant volume, PISA-based effective regurgitant ori

288 imal isovelocity surface area (PISA)-derived regurgitant volume, PISA-derived effective regurgitant o

289 on (grade 4) were 60 mL, 50%, and 40 mm2 for regurgitant volume, regurgitant fraction, and orifice, r

290 RO was not linked to outcome, in contrast to regurgitant volume.

291 regurgitant gradient, a notable increase in regurgitant volume.

292 ted by pulsed-Doppler technique to determine regurgitant volume.

293 based effective regurgitant orifice area and regurgitant volume.

294 red with those with no PPM (change in mitral regurgitant volume: -11+/-4 versus -17+/-5 mL, respectiv

295 ce = 0.51 +/- 1.89 ml/beat for the pulmonary regurgitant volume; and r = 0.91, mean difference = -0.2

296 +/- 2.9 ml vs. 11 +/- 5.8 ml, p < 0.0001 for regurgitant volume; mean difference 1.2 +/- 7.6% vs. 19

297 Regurgitant volumes and regurgitant fractions by the new

298 a promising method for determining pulmonary regurgitant volumes and regurgitant fractions.

299 Pulmonary regurgitant volumes and RV forward stroke volumes comput

300 and agreements between peak and mean RFR and regurgitant volumes per beat as determined by Doppler ec

301 Peak and mean RFRs and regurgitant volumes per beat were calculated from vena c